Cancer cells evolve continuously and co-opt the genomic and metabolic machinery of the tumor micro-environment to confer itself survival & proliferation advantages. These mechanisms employed by cancer cells, known as the ‘hallmarks of cancer’ are key to stopping cancer in its tracks.
At Incozen, our philosophy is to employ a similar a multi-pronged approach, as used by cancer cells, i.e., modulate two or more of its hallmark mechanisms simultaneously in order to vanquish cancer. This approach guides our choice of molecular targets and the pipeline of novel cancer medicines we are developing.
OUR SCIENCE AIMED AT THE HALLMARKS OF CANCER
- Pipeline of novel, targeted, orally active agents with differentiated efficacy & safety for the treatment of hematological cancers
- Providing therapeutic options for refractory and relapsing patients (including genetically characterized variants) alone or in combination with standard of care
Dr Swaroop Vakkalanka
Founder & MD, Incozen Therapeutics
Dr Srikant Viswanadha
Sr VP, Research
Dr Ajit Nair
Sr VP, Clinical Development
Mr Vatsa Natarajan
Sr VP, Development and Commercial Strategy
Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3K δ/ γ Inhibitor in Patients with Relapsed/Refractory Lymphoid MalignanciesRead More +
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyRead More +
Addition of RP6530, a dual PI3Kδ/γ inhibitor, accentuates Romidepsin activity in NHL cells in vitroRead More +
Safety and Anti-Tumour Activity of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib StudyRead More +
Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathwayRead More +
Store-operated calcium signaling is an effective therapeutic target in Acute Myeloid Leukemia (AML)Read More +
Partner With Us
Our approach to partnering is simple and yet effective. We are looking to collaborate with partners having synergistic capabilities and programs. Our successful track record of partnerships with the likes of TG Therapeutics, Novartis etc., bear testimony to our win-win approach.
We have an affiliate entities & offices located across US, EU and India to facilitate our collaborative approach to a developing & commercializing a globally competitive pipeline.Contact Us